PT-141 (Bremelanotide)

Description

PT-141 (Bremelanotide)

Also known as: Bremelanotide, Vyleesi

PT-141 (Bremelanotide) is a synthetic peptide that activates melanocortin receptors and is being studied for its influence on sexual desire, arousal, libido, and overall sexual well-being. Rather than targeting blood flow like many other treatments, PT-141 works within the central nervous system by stimulating receptors linked to sexual response. Because of its ability to boost sexual desire and arousal through non-vascular pathways, it has become a notable focus in sexual health research for both men and women.

• A melanocortin receptor agonist approved by the FDA for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women, developed based on research involving Melanotan II.
• Approved by the FDA, with approval serving as the primary evidence.
• Standard dosage is 1.75 mg taken as needed, administered at least 45 minutes before sexual activity via subcutaneous injection; an autoinjector is available for convenience.
• Investigated for use in addressing low sexual desire, erectile dysfunction, and diminished libido.